Menu

Revvity, Inc. RVTY

Full chart Compare
Set alert

Price alert · RVTY

All alert types
157.91 USD -0.34 (-0.22%)

Nov 12, 2026, 2:26 PM EST

153.04 Day range 159.36
82.26 52-week range 165.78
YTD
+63.21%
1 year
+67.75%
Market cap
17.63B
Revenue (ttm)
2.94B
Profit margin
8.61%
EPS (ttm)
2.25
Shares out
111.59M
P/E ratio
70.19
Forward P/E
26.54
Dividend
0.28 (0.17%)
Ex-dividend date
Jan 21, 2027
YTD return
+63.21%
1-year return
+67.75%
Volume
851.99K
Avg volume
1.91M
Open
156.51
Previous close
158.25
Day's range
153.04 – 159.36
52-week range
82.26 – 165.78
Beta
1.09
Analysts
Buy
Price target
171.07 (+8.3%)
Earnings date
Feb 1, 2027

5D +7.04 (+4.67%)

155160FriMonTueWedThu157.94

Key statistics

Enterprise value
19.96B
PEG ratio
0.98
Price / sales
6.00
Price / book
2.43
Dividend yield
0.18%
Payout ratio
13.40%
Revenue growth
4.30%
Free cash flow
626.77M
Total cash
592.80M
Total debt
2.77B
Return on equity
3.45%
Short % of float
8.76%
50-day average
148.77
200-day average
113.36

Financials — quick view

All financials
RVTY Revenue — quarterly 729.69M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
RVTY Net income — quarterly 51.82M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
RVTY EPS — quarterly 0.47
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

RVTY recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 1, 2027Jan 4, 20271.61———
Nov 3, 2026Oct 4, 20261.301.38+0.08+6.15%
Aug 4, 2026Jul 5, 20261.211.41+0.20+16.53%
May 5, 2026Apr 5, 20261.021.06+0.04+3.92%
Feb 2, 2026Dec 28, 20251.571.70+0.13+8.28%
Oct 27, 2025Sep 28, 20251.141.18+0.04+3.51%

Upgrades / downgrades

RVTY analyst upgrades and downgrades
DateFirmActionFromTo
Nov 4, 2026JP MorganmainNeutralNeutral
Nov 4, 2026TD CowenmainBuyBuy
Nov 4, 2026BarclaysmainEqual-WeightEqual-Weight
Nov 4, 2026RBC CapitalmainSector PerformSector Perform
Nov 4, 2026Evercore ISI GroupmainOutperformOutperform
Oct 13, 2026TD CowenmainBuyBuy

About Revvity, Inc.

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
revvity.com

News

Your note

Sign in to keep a note on RVTY — it syncs with the Stock Master app.

Insider holders

RVTY insider holders
InsiderRelationLatest transactionDateShares held
BARRETT PETERDirectorStock Award(Grant)May 6, 202628,293
CHAPIN SAMUEL R.DirectorStock Award(Grant)May 6, 202622,676
GOLDBERG JOEL SGeneral CounselStock GiftAug 13, 2026105,223
KRAKOWIAK MAXWELLChief Financial OfficerSaleSep 20, 202614,781
MICHAS ALEXANDROS PDirectorStock GiftAug 24, 20260
MICHAS ALEXIS PDirectorSaleAug 26, 20250

Institution ownership

RVTY institution ownership
Holder% heldSharesValueReported
T. Rowe Price Investment Management, Inc.16.37%18,261,1772.89BJun 29, 2026
Jupiter Topco LLC7.74%8,637,6141.37BJun 29, 2026
Edgepoint Investment Group Inc.7.66%8,544,4791.35BJun 29, 2026
Blackrock Inc.6.86%7,658,3691.21BJun 29, 2026
Vanguard Capital Management LLC6.54%7,300,9731.16BJun 29, 2026
Price (T.Rowe) Associates Inc4.96%5,530,850875.04MJun 29, 2026

Fund ownership

RVTY fund ownership
Holder% heldSharesValueReported
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App10.20%11,379,9301.80BJun 29, 2026
JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund4.33%4,828,680763.95MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%3,545,122560.87MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%2,890,294457.27MJun 29, 2026
TR PRICE-Price (T.Rowe) U.S. Value Equity Trust2.41%2,694,775426.34MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%2,557,796404.67MJun 29, 2026